Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
200
NCT05414032
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Phase: Phase 2
Role: Collaborator
Start: Jul 12, 2023
Completion: Jul 31, 2026